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Prognostic significance of xCT polymorphisms and expression in patients 
with advanced pancreatic cancer treated with chemotherapy 
 
Tzu-chuan Jane Huang, MD 
Supervisory Professor: Milind Javle, MD 
 
The plasma membrane xc- cystine/glutamate transporter mediates cellular uptake of 
cystine in exchange for intracellular glutamate and is highly expressed by 
pancreatic cancer cells. The xCT gene, encoding the cystine-specific xCT protein 
subunit of xc-, is important in regulating intracellular glutathione (GSH) levels, critical 
for cancer cell protection against oxidative stress, tumor growth and resistance to 
chemotherapeutic agents including platinum.  We examined 4 single nucleotide 
polymorphisms (SNPs) of the xCT gene in 269 advanced pancreatic cancer patients 
who received first line gemcitabine with or without cisplatin or oxaliplatin. 
Genotyping was performed using Taqman real-time PCR assays.  A statistically 
significant correlation was noted between the 3' untranslated region (UTR) xCT 
SNP rs7674870 and overall survival (OS): Median survival time (MST) was 10.9 
and 13.6 months, respectively, for the TT and TC/CC genotypes (p = 0.027). 
Stratified analysis showed the genotype effect was significant in patients receiving 
gemcitabine in combination with platinum therapy (n = 145): MST was 10.5 versus 
14.1 months for the TT and TC/CC genotypes, respectively (p = 0.013). The 3' UTR 
xCT SNP rs7674870 may correlate with OS in pancreatic cancer patients receiving 
gemcitabine and platinum combination therapy.  Paraffin-embedded core and 
vi 
surgical biopsy tumor specimens from 98 patients with metastatic pancreatic 
adenocarcinoma were analyzed by immunohistochemistry using an xCT specific 
antibody.  xCT protein IHC expression scores were analyzed in relation to overall 
survival in 86 patients and genotype in 12 patients and no statistically significant 
association was found between the level of xCT IHC expression score and overall 
survival (p = 0.514).  When xCT expression was analyzed in terms of treatment 
response, no statistically significant associations could be determined (p = 0.908).  
These data suggest that polymorphic variants of xCT may have predictive value, 
and that the xc- transporter may represent an important target for therapy in 
pancreatic cancer.  
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Chapter 1 
INTRODUCTION 
 
Pancreatic Adenocarcinoma  
In 2011, approximately 44,030 new pancreatic adenocarcinoma cases will be 
diagnosed in the United States, with 37,660 estimated resulting deaths [1].  
Although accounting for only 3% of all new cases of cancer, pancreatic cancer 
continues to be the fourth leading cause of cancer-related death for both men and 
women in the United States [1].  The diagnosis of pancreatic adenocarcinoma 
portends a poor prognosis with a mortality rate nearly matching  its incidence [1].  
This is a highly aggressive cancer that causes substantial disease-related morbidity, 
metastasizes early in its natural history, and exhibits treatment resistance [2].  While 
surgery is the only potentially curative therapeutic modality when a microscopic 
margin negative resection is achieved, only  15–20% of patients have resectable 
pancreatic cancer.  Of these resected early stage pancreatic adenocarcinomas, the 
5-year survival rate is only 20% due to eventual development of metastases [3].  
Despite advances in conventional multimodality approaches of surgery, radiation 
and chemotherapy, mortality rates of pancreatic adenocarcinoma have remained 
relatively unchanged for the last two decades and contribute to a five year overall 
survival rate of less than 4% [2, 4]. For this reason, understanding the contribution 
of molecular mechanisms to disease natural history and identifying novel molecular 
markers are important goals in the management of this cancer.  
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Molecular Heterogeneity in Pancreatic Cancer 
Progressive accumulation of both inherited and acquired mutations leads to the 
molecular heterogeneity of pancreatic adenocarcinoma [5].  This genetic 
heterogeneity can be considered broadly in terms of three main molecular events: 
oncogenic activation driven by genetic mutations, inactivation of tumor suppressor 
genes, and inactivation of genome maintenance genes critical to cellular repair 
mechanisms [6]. The extensive inter-tumor genetic variability existing from 
individual to individual gives rise to multiple permutations of genetic changes. Jones 
et al. demonstrated this high complexity of the pancreatic cancer genome by 
determining each cancer has an average of 63 somatic alterations, most of which 
are point mutations [7].  However, the deregulation of 12 core biological regulatory 
processes or pathways underlie these large numbers of functional genetic 
alterations in the majority of pancreatic tumors [7].  Due to this considerable degree 
of genetic heterogeneity coupled with disappointing survival outcomes with current 
available therapies, patients with pancreatic adenocarcinoma are in particular need 
of a personalized approach to cancer therapy.      
 
Challenges of Current Therapy of Pancreatic Cancer  
The majority of patients present with unresectable late stage locally advanced or 
metastatic disease (stage III or IV) that precludes cure by radiotherapy or surgery 
and have tumors highly resistant to most chemotherapies [8, 9].  Despite the role of 
cytotoxic chemotherapy as the mainstay of pancreatic cancer therapy, most patients 
with pancreatic cancer will eventually progress and develop distant metastatic 
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disease.  For patients with advanced disease, mono- or combination systemic 
chemotherapy that is gemcitabine or fluoropyrimidines-based currently is the 
standard of care.  In metastatic disease, treatment with gemcitabine is associated 
with symptom improvement in more than 20% of patients and offers a slight survival 
benefit (5.65 versus 4.4 month overall median survival) when compared to patients 
treated with 5-fluorouracil [10].  Drug resistance has hindered gains in survival and 
kept beneficial effects largely confined to symptom palliation [11].         
 
Role of Platinum Analogues in Pancreatic Cancer 
Combination chemotherapy in pancreatic cancer has resulted in improved 
outcomes for patients possessing a good functional performance status [12]. The 
combination of gemcitabine and a platinum analogue has become first line standard 
care treatment of advanced pancreatic cancer patients based on results from a 
meta-analysis of randomized trials [13].  While the combination of gemcitabine with 
cisplatin has not yielded significant survival benefit over single agent gemcitabine in 
Phase III studies [14-16], individuals with certain heritable forms of pancreatic 
cancer may exhibit particular disease sensitivity to platinum agents and benefit with 
improved responses to this regimen [17-19].  When compared to gemcitabine 
monotherapy, the addition of oxaliplatin to gemcitabine in advanced pancreatic 
cancer patients has demonstrated clinically significant advantages of superior 
response rates, median progression-free survival, and disease-related symptom 
palliation [20].  More recently, the drug regimen of 5-fluorouracil, leucovorin, 
irinotecan and oxaliplatin (FOLFIRINOX) resulted in more promising results with 
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significant overall survival advantage (10.5 months versus 6.9 months, p>0.001) 
when compared with single agent gemcitabine.  FOLFIRINOX is now considered 
the preferred frontline treatment regimen for good performance status patients with 
unresectable or metastatic pancreatic adenocarcinoma [12].  The improved clinical 
outcomes prompting increased use of platinum analogues in the frontline and 
salvage settings warrant further study of underlying molecular pathways particular 
to platinum resistance. 
 
Platinum Resistance   
Gaining further understanding of drug-resistance mechanisms is essential to 
improving the treatment outcome of patients with pancreatic cancer, as the 
identification of novel targets could lead to the development of therapeutic 
strategies and provide valuable information to optimize patient selection for 
particular drugs.  Studies in pancreatic cancer have shown that acquired and 
intrinsic drug resistance is mediated by multiple mechanisms within or outside the 
cell or at the cell membrane resulting from the dysregulated expression of proteins 
regulating cell proliferation, death, transport and metabolism of drugs, and DNA 
repair [21].Two key DNA repair pathways of nucleotide excision repair and 
mismatch repair are thought to be primary drivers determining sensitivity to cisplatin 
and its analogues [22].  In vitro studies in ovarian and testis tumor cell lines 
demonstrate that deficiency of the excision repair cross-complementation group 1 
(ERCC 1) protein, which is required for the excision of damaged DNA, interrupts the 
highly conserved nucleotide excision repair DNA repair pathway and leads to 
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decreased cisplatin sensitivity [23, 24].  Mismatch repair pathway (MMR) deficiency 
applies to the platinum agents cisplatin and carboplatin.  Inherited genetic changes 
or acquired defects due to epigenetic silencing results in failure of repair proteins to 
recognize mismatched or unmatched DNA base pairs or insertion-deletion loops 
and, thus, inability to correct platinum induced DNA damage [25-28].     As a result, 
cells become resistant to cisplatin and carboplatin, continuing to proliferate despite 
sustaining treatment-generated DNA damage.  Oxaliplatin shows only partial cross 
resistance to cisplatin in preclinical studies [29].  In addition to causing DNA 
damage, preclinical data suggests that cisplatin and oxaliplatin activate cell death 
through generation of reactive oxygen species (ROS); another mechanism of both 
cisplatin and oxaliplatin resistance results from generation of the intracellular 
antioxidant molecule, glutathione (GSH), which mediates elimination of drug-
induced ROS [29, 30, 31] 
 
Cystine-Glutamate Antiporter (System xc-) 
The plasma membrane cystine/glutamate antiporter (system xc-) is an amino acid 
transport system consisting of a light protein subunit with specificity for cystine, xCT 
(SLC7A11 gene), that is coupled to a ubiquitous non-specific heavy protein subunit 
found in other transporters, 4F2hc (SLC3A2 gene) [32]. In human tissues and cells, 
system xc- expression has mainly been demonstrated in the pancreas, along with 
other cells from the brain, stromal and immune system [33].  A variety of cancer 
cells also express system xc-, including prostate cancer, lymphoma, glioma, lung 
cancer and pancreatic cancer [34-37].  xCT transports extracellular cystine 
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(oxidized form of cysteine) in to cells in exchange for the efflux of glutamate in an 
obligate relationship at a 1:1 ratio (Fig 1) [33].  Once inside the cell, the dimeric 
amino acid cystine rapidly reduces to cysteine, the rate-limiting substrate for 
glutathione biosynthesis [38].  GSH is a tripeptide thiol of glutamate, cysteine and 
glycine, functioning as a major protective redox-regulatory molecule against free 
radical induced cellular damage, mutagens, toxins, and drugs [39, 40].  GSH is also 
co-factor for antioxidant enzymes and, thus, is a major reactive oxygen species 
scavenger [41].  Thus, xCT plays a critical role protecting cells by counteracting 
conditions of oxidative stress through its regulation of cystine influx and hence 
intracellular GSH levels and contributing to cellular detoxification of chemotherapy 
[42].   This antiporter keeps the redox relationship between extracellular cystine and 
cysteine in equilibrium [33, 43]. 
 
Fig. 1.  System xc-: Cystine/Glutamate Antiporter and the Pancreatic Cell.   
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Pharmacogenomics & Personalization of Cancer Therapy 
Pharmacogenomics is the study of how an individual’s genotype influences the 
body’s response to drugs and can give insight to drug efficacy in specific patient 
populations.  The term comes from the words pharmacology and genomics and 
represents the intersection of both disciplines.  Germline single nucleotide 
polymorphisms (SNPs) in the gene encoding the detoxification enzyme, uridine 
diphosphate glucuronosyltransferase (UGT) 1A1, have been linked to increased 
toxicity to the drug irinotecan [44].  Patients homozygous for theUGT1A1*28 allele 
metabolize the excretion of the irinotecan metabolite, SN-38, more slowly and are at 
increased risk for neutropenia following this therapy [45, 46].  With FDA approval of 
a test to identify individuals carrying this mutation, identification of this genetic 
variant illustrates the predictive possibilities of SNPs.  These techniques hold 
promise for individualizing and optimizing treatments for patients with pancreatic 
cancer.       
 
xCT and Chemoresistance  
Given the role of xc- system in the maintainance of intracellular GSH, it may play an 
important role in cellular resistance to cisplatin, oxaliplatin and other 
chemotherapeutic agents. System xc- has been demonstrated to contribute to 
chemotherapy resistance in preclinical studies, with resistance of tumor cells to 
anticancer drugs correlated with increased GSH levels.  The level of xCT 
expression can be induced in conditions of oxidative stress and seems also to play 
a role in cancer cell proliferation [37].   Microarray gene expression analysis of 
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system xc- in 60 human cancer cell lines used by the National Cancer Institute for 
drug screening (NCI-60) demonstrated that the level of xCT expression is positively 
correlated with sensitivity of tumor cells to anticancer drugs, with its inhibition 
compromising both cellular redox defense and resistance to multiple drugs [47].  Lo 
et al demonstrated that the highly chemotherapy resistant pancreatic cell line 
PANC-1 expresses higher xCT expression in comparison to pancreatic cell lines 
MIAPaCa-2 and BxPC-3 [37].  Similar findings of higher xCT expression correlated 
with cisplatin resistance also has been demonstrated in resistant human ovarian 
cancer and colon cancer cell lines.  Further, data from in vitro systems have shown 
that inhibition of xCT restores sensitivity to gemcitabine [49].  An understanding of 
the pharmacology including the pharmacogenomics of the xc- system is therefore 
worthy of further study. 
 
From these preclinical observations, the following hypotheses are made: 1) genetic 
variations of the cystine/glutamate transporter are associated with overall survival 
and response to chemotherapy in patients with advanced pancreatic cancer treated 
with gemcitabine +/- cisplatin and 2) high xCT expression in pancreatic cancer 
tissue is associated with a lower overall survival in patients with unresectable 
advanced pancreatic cancer.   
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Chapter 2 
METHODS 
 
Study Population 
Patients were initially identified from patients participating in a case-control study of 
pancreatic cancer conducted at The University of Texas MD Anderson Cancer 
Center (Houston, Texas) from 1999 through 2009.  The study was approved by the 
institutional review board of University of Texas MD Anderson Cancer Center.  The 
eligibility criteria included patients having: a diagnosis of a primary pancreatic ductal 
adenocarcinoma that was pathologically confirmed at MD Anderson, gave consent 
to blood donation, no prior therapy received, and who received first-line single-agent 
gemcitabine or gemcitabine in combination with cisplatin or oxaliplatin treatment at 
MD Anderson.  All patients signed an informed consent for medical record review 
and provided a sample of whole blood by peripheral phlebotomy.  Clinical, 
pathology, and radiographic records of the selected patients were then reviewed 
using the institutional electronic medical records database (ClinicStationTM) to 
confirm their diagnosis and disease stage.  Available outside records which had 
been digitally scanned into the system were also reviewed.  Patients who were seen 
only at their initial visit without subsequent follow up visits at MD Anderson were 
excluded.  Patients who had pancreatic neuroendocrine tumors were also excluded.    
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Clinical Data Collection  
Clinical information was retrieved by reviewing patients' medical records and 
included gender, age at diagnosis, date of pathologic diagnosis, clinical tumor stage 
(resectable, locally advanced, metastasized, and unstaged), serum carbohydrate 
antigen 19-9 (CA19-9) values (unit/mL) at diagnosis, patient performance status, 
chemotherapy received in the first-line setting at the time of metastasis and date of 
death or last follow-up. Overall survival duration was calculated from the time of 
pathologic diagnosis to the date of death or last follow-up. The clinical information 
was double-checked by different researchers.  Clinical response to chemotherapy 
was assessed by evaluation of radiographic reports and determination by the 
treating physicians as documented in clinical progress notes.  The clinical endpoint 
was overall survival and treatment response.   
 
Specimen Collection and DNA Extraction 
Peripheral lymphocytes were collected from freshly drawn blood by Ficoll–Hypaque 
(Amersham Biosciences, Piscataway, NJ) density gradient centrifugation and stored 
at –80 °C. The FlexiGene DNA kit (QIAGEN, Valencia, CA) and the Maxwell 16 
automated system (Promega, Madison, WI) were used to extract DNA, which was 
stored at 4 °C.   
 
Genotyping 
Four functional SNPs located in the coding region (synonymous) or the untranslated 
region (UTR) of the SLC7A11 gene were  selected.  The four SNPs  included three 
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synonymous SNPs of rs35701885, rs4479754, rs6838248 and one 3’-UTR 
(untranslated region) SNP rs7674870.  The gene, chromosome (Chr) location, 
function, amino acid changes and minor allele frequency (MAF) of the 4 SNPs 
evaluated in this study are summarized in Table 1.    
 
Table 1. SNPs evaluated 
Gene Chr   dbSNP 
rs# 
Chr 
Position 
Genomic 
Systematic 
Proteomic 
Systematic                             
Function Wild 
type 
allele 
Variant 
allele 
MAF
* 
SLC7A11 4q28-q32  rs7674870 139308913 Ex12+3709T>C 3’UTR 3’ UTR A C 0.35 
rs35701885 139323865 Ex8+45G>A P320P Synonymous G A 0.04 
rs4479754 139319822 Ex11-2G>A S481S Synonymous A G 0.08 
rs6838248 139359944 Ex5+26C>G Ex5+26C>G Synonymous C G 0.331 
* Allele frequencies obtained from the national center for biotechnology information dbSNP cancer database. 
 
Genotyping was performed using the Taqman 5′ nuclease assay. Primers and 
TaqMan MGB probes were provided by TaqMan SNP Genotyping Assay Services 
(Applied Biosystems, Foster City, CA). PCR was performed in a 5-µL total volume 
consisting of TaqMan Universal PCR Master Mix, 20 ng of genomic DNA (diluted 
with dH2O), and TaqMan SNP genotyping assay mix. Alleles were discriminated by 
running end point detection using an ABI Prism 7900HT sequence detection system 
and SDS 2.3 software (Applied Biosystems, Foster City, CA). Approximately 10% of 
samples were analyzed in duplicate, and inconsistent data were excluded from final 
analysis. 
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Immunohistochemistry 
In addition to the above described cohort, patients with metastatic pancreatic 
adenocarcinoma evaluated at MD Anderson were also identified from their medical 
records.  Pathology records of these patients were then used to determine the 
availability of patient tissue samples.  For patients who had a biopsy or surgical 
procedure at MD Anderson, their formalin fixed paraffin embedded tissue samples 
were requested and obtained from the pathology file room.  For patients treated at 
MD Anderson who received a biopsy or surgery at other institutions, formalin fixed 
paraffin embedded samples from these patients were also requested and obtained 
from outside hospitals.  All patients had their pathologic samples confirmed by a 
pathologist at MD Anderson.   
 
Formulin fixed paraffin-embedded (FFPE) core and surgical biopsy tumor 
specimens from 98 patients with metastatic pancreatic adenocarcinoma were 
analyzed by immunohistochemistry (IHC).  Tissue samples were cut to 4-5 µm thick 
sections using an automated Leica RM2255 rotary microtome and mounted on 
silanized positively charged slides. 
 
FFPE tissue histology sections were deparaffinized, hydrated and incubated for 120 
minutes.  Antigen retrieval was performed using steam preheated to 92-97°C and 
submerged in 0.01 M Citrate at pH 6.  Samples were cooled for 20 minutes at room 
temperature and then washed in 4X PBS for 15 minutes.  Peroxide blocking was 
done with 3% H2O2 in PBS at room temperature for 10 min, followed by washing in 
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4X PBS for 15 minutes, and then blocked with normal serum for 20 minutes at room 
temperature.   
 
Slides were incubated with a rabbit primary polyclonal antibody against xCT (Novus 
Biologicals, LLC, Littleton, CO) at 1:100 dilution at 4°C overnight and then probed at 
room temperature for 60 minutes with the secondary antibody Vectastain Elite 
(Vector Laboratories, Burlingame, CA). Samples were washed for 5 minutes using 
3X PBS and incubated with ABC reagent for 30 minutes. Staining was developed 
with 0.05% 3,3'-Diaminobenzidine (DAB) substrate (Invitrogen, a division of Life 
Technologies Corporation, Carlsbad, CA) and counterstained with hematoxylin.   
 
Grading of IHC slides 
IHC scores were calculated by the product of intensity and extent of xCT expression 
by visualization of 6 fields (staining-intensity X percentage of staining-extent).  The 
intensity of tumor staining for xCT was quantified using a four value intensity score 
that was categorized as:  absent (score 0, non-expressed), very weak (score 1, 
slightly expressed), weak (score 2, expressed), or strong (score 3, highly 
expressed).  Detection of positive staining in ≤50% or >50% resulted in a respective 
score of 1 or 2 for staining extent.  Cells with a final score ≥2 were considered 
positive for protein expression in cytoplasmic (membrane) staining.  
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Survival Measurements 
Overall survival was measured from the date of diagnosis to the date of death or 
last follow-up.  Dates of death were obtained and confirmed using at least one of 
the following three methods: Social Security Death Index 
(www.deathindexes.com/ssdi.html), inpatient medical records, and the MD 
Anderson tumor registry.   
 
Statistical Analysis 
The genotype distribution was tested for Hardy-Weinberg equilibrium with the 
goodness-of-fit Χ2 test.  The heterozygous and homozygous genotypes were 
collapsed in the analysis if the frequency of the homozygous mutant was very low or 
if the homozygous and heterozygous genotypes had the same direction of effect, 
e.g., both had reduced survival time compared to the referent group.   
 
Median survival times (MST) were calculated for all patients.  Kaplan-Meier method 
was used for survival analyses, groups were compared using log-rank test.  Hazard 
ratios and 95% confidence intervals (95% CI) were estimated using univariable or 
multivariate Cox proportional hazard models.  Known or potential prognostic clinical 
factors (CA 19-9, race, performance status) were included in the multivariate model 
when appropriate.  All statistical testing was conducted with SPSS software, version 
17.0 (SPSS), and statistical significance was defined as p < 0.05.  All tests were two 
sided. The false-positive report probability for the observed statistically significant 
association was estimated using the methods described by Wacholder et al [50].  A 
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prior probability of 25% was considered appropriate given the biologic plausibility 
and previous established biostatistical evidence in support of such an association.  
The false-positive report probability value for noteworthiness was set as 0.2.   
 
Immunohistochemistry 
xCT protein IHC expression scores were analyzed in relation to overall survival and 
response to treatment of the patients.  Mean differences of groups were analyzed 
using the one factor ANOVA test. Dichotomous scoring, with 0 representing 
expression scores ≤ 3 and 1 representing expression scores > 3, was also used to 
evaluate the association between the protein expression and overall survival of the 
patients.  Kaplan-Meier method was used for survival analyses, groups were 
compared using log-rank test.  Cox proportional hazard regression models were 
fitted to determine the association between xCT IHC expression and overall 
survival.   Prognostic variables entered into the model included ECOG performance 
status, CA 19-9, and stage.  
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Chapter 3 
RESULTS 
 
SNP Analysis.   
Patient characteristics and clinical predictors  
The patient characteristics are summarized in Table 2.  There were no significant 
differences in overall survival by age, sex, or race of the 269 patients evaluated.  Of 
them, 148 (55%) patients had metastatic disease (stage 4) and 121 (45%) patients 
had locally advanced pancreatic adenocarcinoma (stage 3). 
 
 
Table 2.  SNP Analysis: Patient characteristics (Total n = 269). 
 
Variable Number of 
Patients (n) 
Percentage (%) 
Age 
  <50 
  51-60 
  61-70 
  >70   
 
39 
67 
102 
61 
 
14.5 
24.9 
37.9 
22.7 
Sex 
  Male 
  Female 
 
159 
110 
 
59.1 
40.9 
Race 
  White 
  Hispanic 
  Black 
  Asian 
 
242 
14 
10 
3 
 
90 
5.2 
3.7 
1.1 
Stage 
  3 
  4 
 
121 
148 
 
45 
55 
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We identified three prognostic factors that were significantly associated with 
improved survival outcomes, which include an earlier disease stage, a lower CA 19-
9 tumor marker, and a better performance status (Table 3).   This analysis was 
consistent with previously identified independent prognostic factors in advanced 
pancreatic cancer published in the literature, demonstrating our patients are a 
representative cohort.   
 
 
Table 3.  SNP Analysis: Clinical Prognostic Factors (n=269).   
 
 N. 
patients 
No. 
deaths 
MST 
(months) 
95% CI p 
value 
Stage 
  3 
  4 
 
121 
148 
 
110 
138 
 
15.7 
9.7 
 
13.84-
17.63 
7.95-
11.45 
0.002 
*ECOG Performance 
Status 
  0 
  1 
  2 
 
29 
129 
23 
 
24 
121 
23 
 
15.7 
13.2 
10.4 
 
13.77-
17.7 
11.69-
14.77 
6.94-
13.93 
0.026 
 
CA 19-9 
  <47 
  48-500 
  >500 
 
35 
93 
126 
 
28 
86 
119 
 
17.8 
14.1 
11.4 
 
11.47-
24.13 
12.34-
15.92 
9.65-
13.15 
0.005 
Information was missing from 88 patients. 
 
 
Genotype and association with OS.  
Of the four SNPs evaluated, one showed a significant association with  OS, i.e.  the 
3’ UTR xCT gene SNP, rs7874870.  As shown in Figure 2, patients having CC and 
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TC genotypes had a significantly better overall survival than the TT genotype, the 
median survival time (MST) was 13.7, 13.3, and 10.9 months, respectively  (p value 
= 0.023).  We estimated the false-positive report probability of the xCT SNP 
rs7674870 to be 0.077, given a prior probability of 25%.  It is below the threshold of 
0.20 indicating noteworthiness.    
 
Figure 2.  Kaplan-Meier curve of overall survival in all patients by  the 
rs7674870 genotype.  The genotype is indicated by the blue (TT homozygous), red 
(TC heterozygous) and the green (CC homozygous) lines.     
 
 
 
 
Because of similar survival, the CC and TC groups were combined for further 
statistical analysis.  This range of overall survival is comparable with the general 
population of pancreatic cancer patients and further confirms our study population is 
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a representative cohort.  None of the three synonymous SNPs were found to be 
significantly associated with OS.  The genotype frequencies, MSTs and hazard 
ratios (95% CI) are shown in Table 4.   
 
Table 4.  OS by genotype.  
 
 
 
Stratified analysis showed that this genotype effect remained significant in patients 
receiving gemcitabine in combination with platinum analogs, with MST of 10.5 
months for the TT genotype and 14.1 months for the TC/CC genotypes (p value = 
0.011) (Fig 3).   
 
 
 
 
 
SNP Number of 
patients (n) 
MST (month) HR (95% CI) p value 
rs4479754 
  AA 
  AG 
  GG 
AG/GG 
 
 
260 
4 
1 
 
12.3 
5.9 
9.2 
 
1.0 
 
 
1.2 (0.54-2.66) 
0.646 
rs6838248 
  CC 
  CG 
  GG 
 
 
82 
113 
70 
 
12.7 
12.3 
11.1 
 
 
1.0 
1.01 (0.85-1.19) 
0.990 
rs35701885 
  GG 
  GA 
  AA 
GA/AA 
 
200 
21 
0 
 
12.4 
15.1 
- 
 
1.0 
 
 
0.92 (0.59-1.43) 
 
0.543 
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Figure 3.   Survival by genotype in patients receiving Gemcitabine + Platinum 
Therapy  
 
 
n  
 
 
 
The genotype effect was not significant in patients treated with gemcitabine 
monotherapy, with MST of 10.9 months for TT and 12.0 months for TC/CC 
genotypes (p value = 0.47) (Fig 4).   
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Figure 4.  Overall survival by genotype in patients receiving first-line 
gemcitabine monotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
None of the three synonymous SNPs (rs4479754, rs6838248, and  rs35701885) 
were found to be significantly associated with OS  (Table 4).   
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Immunohistochemistry 
98 patient samples were available for evaluation by immunohistochemistry (Table 
5).  All patients had metastatic pancreatic adenocarcinoma.  There were no 
significant differences in overall survival by age, sex, race or IHC expression score 
of the patients evaluated.  Clinical treatment history was available for 86 samples 
and were eligible for treatment response data analysis.  At the time the data were 
censored, 79.5% of the patient population had died.   
 
 
 
Table 5.  Immunohistochemistry: Patient Characteristics (n=86) 
 
 Number of Patients 
(n) 
Percentage 
(%) 
HR  
(95% CI) 
p value 
Age 
<50 
51-60 
61-70 
>70 
 
16 
25 
31 
14 
 
18.6 
29.1 
36 
16.3 
 
 
 
 
0.995 (0.971-1.020)** 
0.699 
Sex 
Male 
Female 
 
61 
25 
 
70.9 
29.1 
 
1.0 
1.111 (0.614-2.007) 
0.729 
Race 
White 
Hispanic 
Black 
Other 
Non-white 
 
74 
4 
6 
2 
 
86 
4.7 
7 
2.3 
 
1.0 
 
 
 
0.715 (0.479-1.069) 
0.102 
IHC Score* 
Low 
High 
 
36 
48 
 
42.9 
57.1 
 
1.0 
0.924 (0.530-1.614) 
0.782 
Stage 
4 
 
86 
 
100 
  
*2 samples were not evaluable after staining 
**Continuous variable 
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There was no statistically significant association between the level of xCT IHC 
expression score and MST, with 8.8 month MST for high xCT expression and 8.4 
month MST for low xCT expression (p=0.514) (Figure 5, Table 6). 
 
 
Figure 5.  xCT immunohistochemical expression correlated with overall 
survival.   
 
 
 
 
 
 
 
 
Table 6.   xCT IHC and Overall Survival. 
 
 
 Number of  
patients  
Number of 
deaths 
MST 
(months) 
95% CI p value 
Low IHC 
Expression 
44 35 8.8 5.48-12.18  
High IHC 
Expression 
54 48 8.4 5.92-10.81  
Overall 98 83 8.4 6.41-10.32 0.514 
 
           Low expression  
           High expression 
 
             p = 0.514 
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When the mean xCT IHC expression staining score was analyzed in terms of 
patient chemotherapy treatment response, no statistically significant associations 
could be determined (p = 0.908) (Table7,8).  The trend of higher xCT expression, 
however, is consistent with our hypothesis that higher xCT expression is correlated 
with aggressive disease course and with our overall survival data indicating a 
shorter median survival time. 
 
Table 7.  Average IHC Score and Chemotherapy Response.   
 
 
 
 Table 8.  xCT IHC Expression Correlated to Chemotherapy Response.    
 
 
Stratified analysis of xCT immunohistochemical expression score and survival by 
chemotherapy treatment groups of gemcitabine monotherapy and combination 
chemotherapy with gemcitabine and platinum containing agent did not show any 
significant associations (Table 9, 10). 
Response n Mean 95% CI p value 
Progressive disease 37 3.28 2.76-3.82  
Partial response 25 3.12 2.48-3.76  
Stable disease 16 3.16 2.42-3.91  
Total 78 3.21 2.87-3.55 0.908 
Response Score < 3 
n (%) 
Score > 3 
n (%) 
Total 
n (%) 
p value 
Progressive disease 15 (40.5) 22 (59.5) 30  
Partial response 11 (44) 14 (56) 25  
Stable disease 8 (50) 8 (50) 16  
TOTAL with 
response 
34 (43.6) 44 (56.4) 78 0.514 
25 
  
Table 9.  IHC: Survival Analysis of Patients Treated with Gemcitabine (n=36).  
 
Number of 
patients 
Number of 
deaths 
MST 
(months) 
95% CI p value 
Low IHC 
Expression  
18 14 8.83 2.81-14.86  
High IHC 
Expression  
18 15 8.57 6.05-11.08  
Overall 36 29 8.83 6.66-11.00 0.73 
       
 
 
 
Table 10.  IHC: Survival Analysis of Patients Treated with Gemcitabine and 
Platinum Agent (n=43). 
 
 Number of 
patients 
Number of 
deaths 
MST 
(months) 
95% CI p value 
Low IHC 
Expression 
14 13 7.73 3.30-12.17  
High IHC 
Expression 
29 27 8.37 1.58-15.15  
Overall 43 40 7.73 4.41-11.06 0.98 
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Chapter 4 
DISCUSSION 
 
Genomic variations may have predictive value in determining response to 
chemotherapy.  In this study, the associations between xCT gene SNP, rs7674870, 
and clinical outcomes of patients with advanced pancreatic adenocarcinoma were 
evaluated.  To our knowledge, these data are the first to suggest that there is an 
important role for cystine/glutamate antiporter genes in predicting cisplatin 
resistance and in the overall survival of patients with advanced pancreatic cancer.   
 
Our results suggest that the 3’UTR rs7674870 TC/CC genotype was significantly 
associated with OS.  The rs7674870 TC/CC genotype remained as a significant 
predictor for survival after adjusting for all other clinical and genetic factors. Our 
results indicate the correlation between this genotype and OS of patients receiving 
combination chemotherapy with gemcitabine and platinum analogs in predicting 
platinum treatment response.   
 
This study demonstrates that xCT is reliably detectable by immunohistochemistry in 
human pancreatic cancer tissue.  xCT has the functional role of modulating the 
oxidative environment that is critical to protection of the cancer cell against 
xenobiotics through its control of cystine uptake and intracellular glutathione levels 
[51]. Based on preclinical data that system xc- expression is associated with 
gemcitabine resistance, we expected an association of xCT protein expression with 
chemotherapeutic response and OS of patients with metastatic pancreatic cancer.  
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Based upon our results demonstrating a possible role of xCT genotypic variations in 
cisplatin resistance, we expected the patient cohorts treated with combination 
therapy of gemcitabine and platinum to have significant differences in survival 
based on level of xCT expression.  Our data did not show any such significant 
associations.  
 
Many factors may be responsible for these results.  In vitro preclinical pancreatic 
cell line and in vivo functions may not be similar for xCT, and in vitro function may 
not be recapitulated in vivo [52].  Given the discrepancy between in vitro and in vivo 
xCT function, the availability of three different xCT loss of function mouse models 
serve as valuable systems in which to further study xCT function and response to 
pharmacologic manipulation.  In comparison to the technique of Western blotting, 
immunohistochemistry is limiting as a semi-quantitative assay evaluated by visual 
assessment which may depend on inter-observer variability and the target of 
interest.  Further, the immunohistochemical expression of the xCT protein may not 
represent the functional properties of this transporter [37].  
 
We postulated that genetic variations of xCT would manifest in changes of the xCT 
protein detectable by immunohistochemistry and expected a possible association of 
this SNP with xCT protein expression.  An exploratory analysis in 12 patient 
samples demonstrated higher xCT expression was associated with reduced survival 
seen for the TT genotype, which would be consistent with our SNP analysis.  
Though results from this small patient cohort only trended toward statistical 
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significance, further genotypic-phenotypic correlative studies may be worthy for 
future study.  Biologically relevant SNPs may not be best studied by protein 
expression correlative studies as multiple regulatory steps are involved in the 
pathway from gene to protein.  Because synonymous SNPs do not produce altered 
coding sequences, they are not expected to change the function of the protein 
encoded.  However, a previous study has demonstrated that a synonymous SNP in 
the MDR1 gene results in a protein product with altered drug and inhibitor 
interactions [51].  SNPs may also be located at the 3’ and 5’-UTR of DNA.  While 
these sequences do not translate into proteins, the 3’UTR may contain sequence 
motifs crucial for the regulation of transcription, mRNA stability, and cellular location 
of the mRNA or the binding of microRNA [52].  Further studies of xCT mRNA 
expression through utilization of Northern blotting and microRNAs, evolutionarily 
conserved noncoding RNAs that mediate the posttranslational protein modifications 
by binding to 3’ untranslated regions, would be particularly insightful [51]. 
 
Given the increasing use of platinum analogues in the frontline setting with the 
emergence of FOLFIRINOX and continued use of gemcitabine and cisplatin 
combination chemotherapy in advanced pancreatic cancer, our study is especially 
relevant.  With persistent poor survival outcomes for patients with pancreatic 
cancer, clearly a need for greater understanding of underlying mechanisms of 
chemotherapy resistance exists.  This would be important not only for discerning 
disease pathogenesis but also for potentially determining new targets of therapy.  
xCT may represent a viable novel target in pancreatic cancer.  
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Several pharmacologic agents that inhibit system xc- exist [54], exerting therapeutic 
effects primarily by interrupting the antiporter function of cystine uptake into the cell.  
The resulting state of decreased intracellular cystine levels may lead to cellular 
growth inhibition and ultimately cause a state of glutathione depletion, thus reducing 
the ability of the cell to detoxify xenobiotics such as chemotherapy [33].  The 
established FDA approved anti-inflammatory drug, sulfasalazine, has been studied 
as an xCT inhibitor in many different in vitro and in vivo systems.  In vitro, 
sulfasalazine causes growth inhibition of the MIAPaCa and PANC-1 pancreatic 
cancer cell lines [53].  Chung et al. demonstrated that intraperitoneal injection of 
sulfasalazine pharmacologically inhibits system xc- in glioma cells, reducing 
glutathione levels in tumor tissue and slowing tumor growth in an intracranial 
xenograft animal model for human glioma [54].  While sulfasalazine historically 
having excellent safety profile, a trial evaluating sulfasalazine in the treatment of 
progressing malignant gliomas had to be terminated early after interim analysis 
demonstrated significant grade 4 toxicity and patient death on study [55].  Most 
recently, the synthesis of several sulfasalazine analogues possessing a more 
favorable pharmacologic profile demonstrate promise in expanding therapeutic 
options that inhibit system xc- [56].   
 
It is acknowledged that this study has several limitations and that our findings are 
hypothesis generating due to its exploratory nature.  The large number of patients 
with unresectable advanced pancreatic cancer in this study cohort likely reflects a 
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referral bias favoring patients with more severe disease at our institution. A 
selection bias exists due to the retrospective nature of this study. This study 
population was biologically and clinically heterogenic due to the inclusion of patients 
with metastatic pancreatic cancer.  We evaluated rs7674870 in a patient cohort of 
269 patients where 123 received gemcitabine monotherapy and 140 received 
gemcitabine-platinum (cisplatin/oxaliplatin) combination chemotherapy.  xCT 
immunohistochemistry was performed in 98 patients, of whom 36 was treated with 
gemcitabine and 43 was treated with gemcitabine-platinum combination.  In 12 
patients, the association of genotype and immunohistochemical protein expression 
was analyzed.  Hence, the statistical power in terms of prediction and prognosis is 
limited. 
 
Chemotherapy resistance contributes to poor survival outcomes for patients with 
advanced pancreatic cancer.  Our analyses is one of the first to specifically evaluate 
the role of xCT polymorphisms to the chemotherapy sensitivity and survival in 
unresectable pancreatic cancer.  In conclusion, genotypes of system xc- xCT 
transporter genes have potential as predictive biomarkers for cisplatin response and 
efficacy in unresectable advanced pancreatic cancer.  This study establishes that 
human xCT can be reliably detected and qualitatively scored by 
immunohistochemistry.  Prospective validation of these results in additional 
datasets and human functional pharmacologic inhibitor studies are needed.   
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